17-Hydroxyprogesterone (17-OHP) in urine is greatly elevated in patients with polycystic ovarian disease and in patients with idiopathic hirsutism. Wong and coworkers showed that measurement of 17-OHP in 24-hour urine produced results that may be useful for monitoring glucocorticoid and mineralocorticoid therapy in patients with congenital adrenal hyperplasia (CAH).¹ Other studies have shown that 17-OHP in 24-hour urine correlated well with serum 17-OHP and suggested that the urine measurement of 17-OHP may be a reliable alternative to serum 17-OHP measurement for monitoring of CAH therapy.^2,3

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

1. Wong ET, Brown DR, Ulstrom RA, Steffes MW. Urinary 17 alpha-hydroxyprogesterone in diagnosis and management of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1979 Sep; 49(3):377-380. PubMed 468971

2. Lim YJ, Yong AB, Warne GL, Montalto J. Urinary 17 alpha-hydroxyprogesterone in management of 21-hydroxylase deficiency. J Paediatr Child Health. 1995 Feb; 31(1):47-50. PubMed 7748691

3. Shibata Y. Determination of urinary 17 alpha-hydroxyprogesterone excretion using ELISA--evaluation of normal subjects and patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Nihon Naibunpi Gakkai Zasshi. 1991 Aug 20; 67(8):819-839. PubMed 1813324

Use random urine transport tube containing 6N HCl or urine Monovette® with pH stabilizer (LabCorp N° 56015). Monovette® instructions accompany units. Preservative must be added to the container prior to the start of the collection. If collecting without Monovette®, use plastic urine container and adjust urine pH to <5 with 6N HCl. Caution: Strong acid. May cause skin burns.

Refrigerate.